The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure
Open accessAbstract
BACKGROUND: An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, and a heart rate of 70 beats per minute or more. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more (including 12,049 patients with activity-limiting angina [class ≥II on the Canadian Cardiovascular Society scale, which ranges from I to IV, with higher classes indicating greater limitations on physical activity owing to angina]). We randomly assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. The primary end point was a composite of death from cardiovascular causes or nonfatal myocardial infarction. RESULTS: At 3 months, the mean (±SD) heart rate of the patients was 60.7±9.0 beats per minute in the ivabradine group versus 70.6±10.1 beats per minute in the placebo group. After a median follow-up of 27.8 months, there was no significant difference between the ivabradine group and the placebo group in the incidence of the primary end point (6.8% and 6.4%, respectively; hazard ratio, 1.08; 95% confidence interval, 0.96 to 1.20; P=0.20), nor were there significant differences in the incidences of death from cardiovascular causes and nonfatal myocardial infarction. Ivabradine was associated with an increase in the incidence of the primary end point among patients with activity-limiting angina but not among those without activity-limiting angina (P=0.02 for interaction). The incidence of bradycardia was higher with ivabradine than with placebo (18.0% vs. 2.3%, P<0.001). CONCLUSIONS: Among patients who had stable coronary artery disease without clinical heart failure, the addition of ivabradine to standard background therapy to reduce the heart rate did not improve outcomes. (Funded by Servier; SIGNIFY Current Controlled Trials number, ISRCTN61576291.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the indication of stable coronary disease, none of these medications have been shown to reduce the risk of mortality or myocardial infarction.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [249]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationGibbons, R. J., Abrams, J., Chatterjee, K., Daley, J., DEEDWANIA, P. C., Douglas, J. S., Ferguson, T. B., Fihn, S. D., Fraker, T. D., Gardin, J. M., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02848-6 · Cited by 1,685
Guidelines on the management of stable angina pectoris: executive summary
Authors/Task Force Members, Fox, K. M., Garcia, M. A. A., Ardissino, D., Buszman, P. E., Camici, P. G., Crea, F., Daly, C., Backer, G. D., Hjemdahl, P., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl001 · Cited by 1,332
Self-citationHeart rate and cardiovascular mortality: The Framingham study
Kannel, W. B., Kannel, C., Paffenbarger, R. S., & Cupples, L. A. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90666-1 · Cited by 1,292
Böhm, M., Swedberg, K. B., Michel Komajda, N., BORER, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61259-7 · Cited by 1,100
Self-citationFox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099
Self-citationResting Heart Rate in Cardiovascular Disease
Fox, K., Borer, J. S., Camm, A. J., Danchin, N., Ferrari, R., Lopez Sendon, J. L., Steg, P. G., Tardif, J.-C., Tavazzi, L., & Tendera, M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.079 · Cited by 1,062
Self-citationDiaz, A., Bourassa, M. G., Guertin, M.-C., & Tardif, J.-C. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi190 · Cited by 790
Self-citationFox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61171-x · Cited by 789
Self-citationTardif, J., Ford, I., Tendera, M., Bourassa, M. G., & Fox, K. M. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi586 · Cited by 580
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 485
Stable coronary artery disease
Tanna, M. S., Messerli, F. H., & Bangalore, S. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002041 · Cited by 13
Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase
Marini, I., Moschini, R., CORSO, A. D., & Mura, U. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4474-z · Cited by 13
Heart rate in chronic heart failure: an overlooked risk factor
Michel Komajda, N. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu440 · Cited by 13
Habel, N., Infeld, M. M., Lustgarten, D. L., & Meyer, M. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.064 · Cited by 15
Weissler‐Snir, A., Rakowski, H., & Meyer, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad518 · Cited by 12
Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies
Lachowska, K., Gruchała, M., Narkiewicz, K., & Hering, D. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0660-7 · Cited by 12
Vaillant, F., Lauzier, B., Ruiz, M., Shi, Y., Lachance, D., Rivard, M.-È., Bolduc, V., Thorin, É., Tardif, J., & Rosiers, C. D. (2016) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00789.2015 · Cited by 12
Self-citationThe Challenges with Chronic Angina
Ohman, E. M., & Alexander, K. P. (2014) · New England Journal of Medicine · doi:10.1056/nejme1409369 · Cited by 12
The Medical Treatment of Stable Angina
Kwon, L., & Rosendorff, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00020-0 · Cited by 11
van Hoof, R. H. M., Hermeling, E., Sluimer, J. C., Salzmann, J., Hoeks, A. P. G., Roussel, J., Daemen, M. J. A. P., Struijker-Boudier, H. A. J., Wildberger, J. E., Heeneman, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179024 · Cited by 11
Antianginal Efficacy of Ivabradine in Patients With History of Coronary Revascularization
Zarifis, J., Grammatikou, V., Kallistratos, M. S., & Katsivas, A. G. (2016) · Angiology · doi:10.1177/0003319716630499 · Cited by 11
Ivabradine has a neutral effect on mortality in randomized controlled trials
Kang, S., Li, C.-J., & Zhang, X. (2017) · Medicine · doi:10.1097/md.0000000000008067 · Cited by 11
Timmis, A., Raharja, A., Archbold, A., & Mathur, A. (2018) · Heart · doi:10.1136/heartjnl-2018-313230 · Cited by 11
Fontenla, A., López‐Gil, M., Tamargo-Menéndez, J., Matía‐Francés, R., Salgado‐Aranda, R., Rey-Blas, J. R., Blanco, Á. M., Mejía-Martínez, E., Fuentes, A. P., Toquero‐Ramos, J., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.06.006 · Cited by 11
Adjuvant treatment of coronary heart disease angina pectoris with Chinese patent medicine
Liu, Y., Zhu, L., Shen, D., Song, Y., Huang, M., Xue, X., Xie, J., Jiao, Z., Gao, S., Xu, Y., et al. (2019) · Medicine · doi:10.1097/md.0000000000016884 · Cited by 11
Ivabradine and AF: Coincidence, Correlation or a New Treatment?
Abdelnabi, M. H., Ahmed, A. U., Almaghraby, A. M., Saleh, Y., & Badran, H. (2020) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2019.30.2 · Cited by 11
Betancourt, V. D., Chinda, K., Mesirca, P., Barr�re, C., Covinhes, A., Gallot, L., Vincent, A., Bidaud, I., Kumphune, S., Nargeot, J., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1134503 · Cited by 10
Nonpharmacological Approaches to Managing Heart Failure With Preserved Ejection Fraction
Tang, F., Han, H., Fu, S., Liu, Q., Zhou, S., Huang, J., & Xiao, Y. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.011269 · Cited by 10
Cao, X., Sun, Z., Zhang, B., Li, X., & Xia, H. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447901 · Cited by 10
Çavuşoğlu, Y., Altay, H., Ekmekçi, A., Eren, M., Küçükoğlu, M. S., Nalbantgil, S., Sarı, İ., Selçuk, T., Temizhan, A., Ural, D., et al. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6767 · Cited by 10
Awasthi, G., Arora, V., Singh, R., & Singh, V. (2019) · Anesthesia Essays and Researches · doi:10.4103/aer.aer_175_18 · Cited by 10
Maagaard, M., Nielsen, E. E., Sethi, N. J., Liang, N., Yang, S.-H., Gluud, C. N., & Jakobsen, J. C. (2020) · Open Heart · doi:10.1136/openhrt-2020-001288 · Cited by 10
The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region
Cheng, K., Al-Humood, K., Elshaer, F., & de Silva, R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01582-w · Cited by 10
Ivabradine and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
Wang, Z., Wang, W., Li, H., Zhang, A., Han, Y. Y., Wang, J., & Hou, Y. (2022) · PubMed · doi:10.1097/fjc.0000000000001209 · Cited by 9
Actualización en cardiopatía isquémica y cuidados críticos cardiológicos
Sionís, A., Ruiz-Nodar, J. M., Fernández‐Ortíz, A., Marín, F. R., Abu‐Assi, E., Dı́az-Castro, Ó., Nuñez-Gil, I. J., & Lidón, R. M. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.11.013 · Cited by 9
Ivabradine in Patients Undergoing Noncardiac Surgery: A Randomized Controlled Trial
Szczeklik, W., Fronczek, J., Putowski, Z., Włudarczyk, A., Górka, J., Seczyńska, B., Gryszówka, D., Widawska, A., Białka, S., Palaczyński, P., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.076704 · Cited by 9
Update on Ischemic Heart Disease and Intensive Cardiac Care
Sionís, A., Ruiz-Nodar, J. M., Fernández‐Ortíz, A., Marín, F. R., Abu-Assi, E., Dı́az-Castro, Ó., Nuñez-Gil, I. J., & Lidón, R. M. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.11.008 · Cited by 9
The year in cardiology 2014: prevention
Backer, G. D., Kastelein, J. J. P., & Landmesser, U. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu482 · Cited by 9
What is the role of coronary angioplasty and stenting in stable angina?
Al-Lamee, R. K., Davies, J. E., & Malik, I. S. (2016) · BMJ · doi:10.1136/bmj.i205 · Cited by 9
van Ockenburg, S. L., Rosmalen, J. G. M., Bakker, S. J. L., de Jonge, P., & Gans, R. O. B. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.030 · Cited by 9
Chen, A. B., Elia, N., Dunaiceva, J., Rudiger, A., Walder, B., & Pinto, B. B. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.01.027 · Cited by 9
Effect of Ivabradine on Cardiac Ventricular Arrhythmias: Friend or Foe?
Oknińska, M., Paterek, A., Zambrowska, Z., Mackiewicz, U., & Ma̧czewski, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10204732 · Cited by 9
Seimon, R. V., Espinoza, D., Finer, N., James, W. P. T., Legler, U. F., Coutinho, W. F., Sharma, A. M., Gaal, L. V., Maggioni, A. P., Sweeting, A., et al. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.211 · Cited by 9
Kitai, T., & Tang, W. H. W. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-015-0435-5 · Cited by 9
Experimental and early investigational drugs for angina pectoris
Elgendy, I. Y., Winchester, D. E., & Pepine, C. J. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1254617 · Cited by 9
Advancements in pharmacotherapy for angina
Jain, A., Elgendy, I. Y., Al‐Ani, M. A., Agarwal, N., & Pepine, C. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1303483 · Cited by 9
How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure
da Silva, R. M. F. L., Borges, A. S. R., Penha‐Silva, N., Resende, E. S., Tse, G., Liu, T., Roever, L., & Biondi‐Zoccai, G. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0757-3 · Cited by 9
Meyer, M., Núñez, J. E., Goyal, P., Silverman, D. N., van Berlo, J. H., & Maharaj, V. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.22 · Cited by 8
Physiological effects of ivabradine in heart failure and beyond
Iness, A. N., Shah, K., & Kukreja, R. C. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04862-5 · Cited by 8
Beta Blockers in Contemporary Cardiology: Is It Better to Cast Them Out?
Dar, J. A., & Jacob, J. R. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2023.0209 · Cited by 8
Raoufinia, R., Rahimi, H. R., Abbaszadeh, M., Gholoobi, A., Saburi, E., Fakoor, F., Alshakarchi, H. I., Gataa, I. S., Hassanian, S. M., Ferns, G. A., et al. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128309440240427102903 · Cited by 8
Shoji, S., & Mentz, R. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10412-y · Cited by 8
Heusser, K., Tank, J., Brinkmann, J., Schroeder, C., May, M., Großhennig, A., Wenzel, D., Diedrich, A., Sweep, F. C. G. J., Mehling, H., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002674 · Cited by 8
Angina treatments and prevention of cardiac events: an appraisal of the evidence: Table 1
Winchester, D. E., & Pepine, C. J. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv054 · Cited by 8
Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease
Cacciapuoti, F. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716636042 · Cited by 8
Ivabradine and endothelium: an update
Dallapellegrina, L., Sciatti, E., & Vizzardi, E. (2020) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944720934937 · Cited by 8
Amstetter, D., Badt, F., Rubi, L., Bittner, R. E., Ebner, J., Uhrín, P., Hilber, K., Koenig, X., & Todt, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173818 · Cited by 8
Wang, B., Zhang, X., Chen, J., Chen, S., Chen, Q., Yang, S., & Wang, Q. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-563 · Cited by 8
Poppe, K., Doughty, R. N., Wells, S. J., Wu, B., Earle, N. J., Richards, M., Troughton, R. W., Jackson, R., & Kerr, A. (2019) · Heart · doi:10.1136/heartjnl-2019-315809 · Cited by 8
Infeld, M. M. (2024) · Heart Rhythm O2 · doi:10.1016/j.hroo.2024.03.009 · Cited by 7
Asymmetric Synthesis of Scillascillin-Type Homoisoflavonoid
Wang, H., Gao, Z., Wang, J., Chen, D., Wang, Y., Sun, H., Hao, H., & Li, R. (2024) · Organic Letters · doi:10.1021/acs.orglett.3c03968 · Cited by 7
Clinical Implications of Ivabradine in the Contemporary Era
Imamura, T. (2024) · Medicina · doi:10.3390/medicina60020303 · Cited by 7
On behalf of the RESPONSIfVE study investigators, Perings, S. M., Stöckl, G., & Kelm, M. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0377-7 · Cited by 7
Ivabradine: Do the Benefits Outweigh the Risks?
Alshammari, T. M. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416672008 · Cited by 7
The Use and Indication of Ivabradine in Heart Failure
Dodd, K. S., & Lampert, B. C. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.06.001 · Cited by 7
Effects of Ivabradine on Residual Myocardial Ischemia after PCI Evaluated by Stress Echocardiography
Calcagno, S., Infusino, F., Dettori, O., Taccheri, T., Bruno, P., Maestrini, V., Sardella, G., Mancone, M., & Fedele, F. (2019) · Cardiology Research and Practice · doi:10.1155/2019/9185876 · Cited by 7
Effect of Preoperative Ivabradine on Hemodynamics during Elective Off-Pump CABG
Virmani, S., Mallik, I., Mohire, V. B., Geelani, M. A., & Minhas, H. S. (2023) · Annals of Cardiac Anaesthesia · doi:10.4103/aca.aca_97_22 · Cited by 7
Qin, S., Huang, L., Zhou, J., Wang, H., Li, Q., Wu, H., & Wu, J. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s330726 · Cited by 7
Nocturnal heart rate and cerebrovascular disease
Yano, Y. (2015) · Hypertension Research · doi:10.1038/hr.2015.58 · Cited by 7
A genetic model of ivabradine recapitulates results from randomized clinical trials
Legault, M., Sandoval, J., Provost, S., Barhdadi, A., Perreault, L. L., Shah, S. H., Lumbers, R. T., de Denus, S., Tyl, B., Tardif, J., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236193 · Cited by 7
Self-citationMaximum heart rate and mortality in sepsis patients: a retrospective cohort study
Shen, Y., Wang, J., Cao, Q., Wu, Y., Wang, Q., Wang, N., & Shao, M. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03960-0 · Cited by 6
Validation of a predictive model for coronary artery disease in patients with diabetes
Xu, J., Zhao, Q., Li, J., Yuan, Y., Cao, X., Zhang, X., Jia, F., Yan, W., Wang, B., Li, Y., et al. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001387 · Cited by 6
Clark, A. L., & Pellicori, P. (2014) · ESC Heart Failure · doi:10.1002/ehf2.12012 · Cited by 6
Overview of Management of Myocardial Ischemia: a Mechanistic-Based Approach
Lanza, G. A., & Crea, F. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6662-5 · Cited by 6
Núñez, L., Crespo-Leiro, M. G., Marrón-Liñares, G. M., Suárez-Fuentetaja, N., Barge‐Caballero, E., Paniagua-Martín, M. J., Marzoa‐Rivas, R., Grille-Cancela, Z., Muñiz, J., Vázquez‐Rodríguez, J. M., et al. (2013) · Cardiology Journal · doi:10.5603/cj.a2016.0050 · Cited by 6
Inoue, T., Arima, H., Katsuimata, Y., Iseki, C., Kinjo, K., & Iseki, K. (2019) · Angiology · doi:10.1177/0003319719870950 · Cited by 6
Tekin, E. E., Yeşiltaş, M. A., & Haberal, İ. (2022) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2021-0201 · Cited by 6
Comentarios a la guía ESC 2019 sobre síndromes coronarios crónicos
Grupo de Trabajo de la SEC para la guía ESC 2019 sobre síndromes coronarios crónicos, R. E. P. L. G. E. 2. S. S. C. C. Y. C. D. G. D. L. S. (2020) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.12.013 · Cited by 6
Hossain, M. U., Ferdous, N., Reza, M. N., Ahammad, I., Tiernan, Z., Wang, Y., O’Hanlon, F., Wu, Z., Sarker, S., Mohiuddin, A. K. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25102-8 · Cited by 6
Wang, J., Lu, W., Li, J., Zhang, R., Zhou, Y., Yin, Q., Zheng, Y., Wang, F., Xia, Y., Chen, K., et al. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4210 · Cited by 6
Hellenbart, E. L., Griffin, T., & DiDomenico, R. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2391 · Cited by 6
Ivabradine for the Therapy of Chronic Stable Angina Pectoris: a Systematic Review and Meta-Analysis
Kalvelage, C., Stoppe, C., Marx, N., Marx, G., & Benstoem, C. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2020.0031 · Cited by 6
A New Investigation into the Molecular Mechanism of Andrographolide towards Reducing Cytokine Storm
Alzahrani, A. (2022) · Molecules · doi:10.3390/molecules27144555 · Cited by 6
Ivabradine, Heart Failure and Chronic Kidney Disease
Lullo, L. D., Bellasi, A., Russo, D., Cozzolino, M. G., Ronco, C., Santoboni, A., & Barbera, G. (2015) · Nephrology Point of Care · doi:10.5301/poc.5000190 · Cited by 6
Funny and Late: Targeting Currents Governing Heart Rate in Atrial Fibrillation
Daniels, J. D., & Hill, J. A. (2014) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12597 · Cited by 6
Role of ivabradine and heart rate lowering in chronic heart failure: guideline update
Chow, S. L., Page, R. L., II, & Depré, C. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1489235 · Cited by 6
Commentary: The new ESC guidelines for the diagnosis and management of chronic coronary syndromes
Camici, P. G., Crea, F., & Ferrari, R. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.10.001 · Cited by 6
Self-citationy, P. A., Bayés‐Genís, A., de Isla, L. P., & Sanchís, J. M. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.09.003 · Cited by 5
Kolapkar, V., Mohan, J. C., Sathyamurthy, I., Panja, M., Agarwala, R., Ponde, C. K., Kumar, A. S., Mahala, B. K., Kumar, R. V. L., & Patel, K. (2023) · Current Cardiology Reviews · doi:10.2174/1573403x19666230320105623 · Cited by 5
Lin, C.-H., Zhang, J., Kuo, Y., Kuo, C., Huang, Y.-C., Lee, M., & Lee, J.-D. (2024) · BMC Neurology · doi:10.1186/s12883-024-03772-3 · Cited by 5
Agreement Between Mega-Trials and Smaller Trials
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.32296 · Cited by 5
Update on ivabradine for heart failure
BORER, J. S., & Tavazzi, L. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.01.004 · Cited by 5
Ivabradine improves left ventricular twist and untwist during chronic hypertension
Jozwiak, M., Melka, J., Rienzo, M., Bizé, A., Sambin, L., Hittinger, L., Berdeaux, A., Su, J. B., Bouhemad, B., & Ghaleh, B. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.11.049 · Cited by 5
Cada, D. J., Bindler, R. J., & Baker, D. E. (2015) · Hospital Pharmacy · doi:10.1310/hpj5009-806 · Cited by 5
Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review
Hajiqasemi, M., Ebrahimzade, M., Ghelichkhan, Z. A., Huang, X., Morkos, D., Jennings, D. L., & Talasaz, A. H. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001609 · Cited by 6
Parma, Z., Young, R., Roleder, T., Marona, M., Ford, I., Tendera, M., Steg, P. G., & Stępińska, J. (2019) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.14789 · Cited by 6
Self-citationÇinier, G., Hayıroğlu, M. İ., Özcan, K. S., Pay, L., Tekkeşin, A. İ., & Gürkan, K. (2022) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2021.12.010 · Cited by 5
Functional Angioplasty: Definitions, Historical Overview, and Future Perspectives
Park, H., Kang, D., & Lee, C. W. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0363 · Cited by 5
Kardiovaskuläre Pharmakotherapie und koronare Revaskularisation bei terminaler Niereninsuffizienz
Lauder, L., Ewen, S., Emrich, I. E., Böhm, M., & Mahfoud, F. (2019) · Herz · doi:10.1007/s00059-019-04846-6 · Cited by 5
The Prognostic Value of Resting Heart Rate for Health Status
Park, D., & Jeon, J. Y. (2020) · Exercise Science · doi:10.15857/ksep.2020.29.1.24 · Cited by 5
Ivabradine-Induced Torsade de Pointes in Patients with Heart Failure Reduced Ejection Fraction
Jang, J.-H., Kwon, S. W., Lee, M., Ko, K., Park, J., Yoon, G.-S., Choi, S., Beak, Y.-S., Park, S., Shin, S., et al. (2020) · International Heart Journal · doi:10.1536/ihj.20-073 · Cited by 5
The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice
Xing, R., Moerman, A. M., Ridwan, R. Y., van Gaalen, K., Meester, E. J., van der Steen, A. F. W., Evans, P. C., Gijsen, F. J. H., & der Heiden, K. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-32458-3 · Cited by 5
Triple antianginal combinations in the treatment of elderly and senile patients with stable angina
Канорский, С. Г., & Smolenskaya, N. V. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh2016881233-40 · Cited by 5
Moovendhan, M., Kavisri, M., Vairamani, S., & Shanmugam, A. (2021) · Biomass Conversion and Biorefinery · doi:10.1007/s13399-021-01650-3 · Cited by 4
Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine Therapy
DIXIT, K., & Frishman, W. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000503 · Cited by 4
Lukito, E. W., Iswantini, D., Antariksa, B., Rafi, M., & Wahyudi, S. T. (2024) · Pharmacognosy Journal · doi:10.5530/pj.2024.16.18 · Cited by 4
Stable Angina Pectoris: A Review of Pathophysiology, Diagnosis, and Its Management
Sharma, A., Roy, T., Bhattacharya, P., Agarwal, D. K., Kumar, R., Naqvi, S. M. H., & Mittal, R. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0704 · Cited by 4
Treatment for Inappropriate Sinus Tachycardia
Adum, J. P. S., & Arora, R. R. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000335 · Cited by 4
Ivabradine in Coronary Heart Disease—The Emperor Has No Clothes
Messerli, F. H., Rimoldi, S. F., & Bangalore, S. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.05.033 · Cited by 4
Godino, C., Colombo, A., & Margonato, A. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0472-1 · Cited by 4
Metadata
- Authors
- Fox, K., Ford, I., Steg, P. G., Tardif, J.-C., Tendera, M., & Ferrari, R.
- Affiliations
- Inserm (FR)
- University of Glasgow (GB)
- Montreal Heart Institute (CA)
- University of Ferrara (IT)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-18
- Volume
- 371
- Issue
- 12
- Pages
- 1091-1099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2153622558
- Cited by
- 486
- References
- 19
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 30 · 2023: 34 · 2022: 29 · 2021: 29 · 2020: 27 · 2019: 44 · 2018: 35 · 2017: 49 · 2016: 95 · 2015: 68 · 2014: 18
- FWCI
- 52.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10149)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- ivabradine, stable coronary artery disease, heart rate reduction, cardiovascular mortality, myocardial infarction, bradycardia, non-inferiority, left ventricular dysfunction, target heart rate, drug safety and efficacy, atrial fibrillation
- MeSH terms
- Ivabradine, Adrenergic beta-Antagonists, Aged, Angiotensin-Converting Enzyme Inhibitors, Benzazepines, Cardiovascular Diseases, Coronary Artery Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heart Failure, Heart Rate, Humans, Male, Middle Aged, Risk, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Intention to Treat Analysis, Angina, Stable
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
